P-347 A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma: EMERALD-1

Bruno Sangro, Masatoshi Kudo, Shukui Qin, Zhenggang Ren, Stephen L. Chan, Eric W. Joseph, Yosuke Arai, Helen Mann, Shethah Morgan, Geoffrey L. Cohen, Riccardo Lencioni